Trop2-targeted therapy in breast cancer.

IF 9.5 2区医学 Q1 MEDICINE, RESEARCH & EXPERIMENTAL

Biomarker Research Pub Date : 2024-08-13 DOI:10.1186/s40364-024-00633-6

Yixuan Hu, Yinxing Zhu, Dan Qi, Cuiju Tang, Wenwen Zhang

{"title":"Trop2-targeted therapy in breast cancer.","authors":"Yixuan Hu, Yinxing Zhu, Dan Qi, Cuiju Tang, Wenwen Zhang","doi":"10.1186/s40364-024-00633-6","DOIUrl":null,"url":null,"abstract":"<p><p>Human trophoblastic cell surface antigen 2 (Trop2) is a glycoprotein, a cellular marker of trophoblastic and stem cells, and a calcium signaling transducer involved in several signaling pathways, leading to the proliferation, invasion, and metastasis of tumors. It is expressed at a low level in normal epithelial cells, but at a high level in many tumors, making it an ideal target for cancer therapy. According to previous literature, Trop2 is broadly expressed in all breast cancer subtypes, especially in triple negative breast cancer (TNBC). Several clinical trials have demonstrated the effectiveness of Trop2-targeted therapy in breast cancer. Sacituzumab govitecan (SG) is a Trop2-targeted antibody-drug conjugate (ADC) that has been approved for the treatment of metastatic TNBC and hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-negative (HER2-) breast cancer. This article reviews the structure and function of Trop2, several major Trop2-targeted ADCs, other appealing novel Trop2-targeted agents and relevant clinical trials to provide a landscape of how Trop2-targeted treatments will develop in the future.</p>","PeriodicalId":54225,"journal":{"name":"Biomarker Research","volume":"12 1","pages":"82"},"PeriodicalIF":9.5000,"publicationDate":"2024-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11321197/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biomarker Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s40364-024-00633-6","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}

引用次数: 0

Abstract

Human trophoblastic cell surface antigen 2 (Trop2) is a glycoprotein, a cellular marker of trophoblastic and stem cells, and a calcium signaling transducer involved in several signaling pathways, leading to the proliferation, invasion, and metastasis of tumors. It is expressed at a low level in normal epithelial cells, but at a high level in many tumors, making it an ideal target for cancer therapy. According to previous literature, Trop2 is broadly expressed in all breast cancer subtypes, especially in triple negative breast cancer (TNBC). Several clinical trials have demonstrated the effectiveness of Trop2-targeted therapy in breast cancer. Sacituzumab govitecan (SG) is a Trop2-targeted antibody-drug conjugate (ADC) that has been approved for the treatment of metastatic TNBC and hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-negative (HER2-) breast cancer. This article reviews the structure and function of Trop2, several major Trop2-targeted ADCs, other appealing novel Trop2-targeted agents and relevant clinical trials to provide a landscape of how Trop2-targeted treatments will develop in the future.

查看原文本刊更多论文

乳腺癌的 Trop2 靶向治疗。

人类滋养层细胞表面抗原 2（Trop2）是一种糖蛋白，是滋养层细胞和干细胞的细胞标记物，也是一种钙信号转导物，参与多种信号通路，导致肿瘤的增殖、侵袭和转移。它在正常上皮细胞中的表达量较低，但在许多肿瘤中的表达量却很高，因此是癌症治疗的理想靶点。根据以往的文献，Trop2 在所有乳腺癌亚型中都有广泛表达，尤其是在三阴性乳腺癌（TNBC）中。一些临床试验已经证明了Trop2靶向疗法在乳腺癌中的有效性。萨妥珠单抗戈维替康（SG）是一种Trop2靶向抗体-药物共轭物（ADC），已被批准用于治疗转移性TNBC、激素受体阳性（HR+）和人表皮生长因子受体2阴性（HER2-）乳腺癌。本文回顾了Trop2的结构和功能、几种主要的Trop2靶向ADC、其他有吸引力的新型Trop2靶向药物和相关临床试验，为Trop2靶向治疗在未来的发展提供了一个前景。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Biomarker Research Biochemistry, Genetics and Molecular Biology-Molecular Medicine

CiteScore

15.80

自引率

1.80%

发文量

审稿时长

10 weeks

期刊介绍： Biomarker Research, an open-access, peer-reviewed journal, covers all aspects of biomarker investigation. It seeks to publish original discoveries, novel concepts, commentaries, and reviews across various biomedical disciplines. The field of biomarker research has progressed significantly with the rise of personalized medicine and individual health. Biomarkers play a crucial role in drug discovery and development, as well as in disease diagnosis, treatment, prognosis, and prevention, particularly in the genome era.